Skip to main content

Table 1 Patient characteristics

From: Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

Variable

All patients (n = 26)

Sensitive (n = 18)

Primary resistant (n = 8)

Age (years), median (range)

60 (20–80)

61 (40–79)

58 (20–80)

Sex, n (%)

 Female

11 (42)

8 (44)

3 (38)

 Male

15 (58)

10 (56)

5 (62)

Histology, n (%)

 Clear cell carcinoma

17 (65)

13 (72)

4 (50)

 Papillary carcinoma

3 (12)

1 (6)

2 (25)

 Mixed type1

6 (23)

4 (22)

2 (25)

Prior systemic therapy, n (%)

 0

17 (65)

10 (55)

7 (88)

 1

8 (31)

7 (39)

1 (12)

 2

1 (4)

1 (6)

–

PFS (months), median (range)

 

8.8 (5–62.3)

2.3 (1.5–2.8)

Time to sunitinib (months), median (range)

6 (1–63)

6 (1–63)

6 (1–24)

  1. 1 Consists of more than one histological type: clear cell + papillary, clear cell + sarcomatoid, clear cell + eosinophilic variant. Time to sunitinib indicates interval between resection and initiation of sunitinib treatment; PFS, progression-free survival
Back to article page

Clinical Proteomics

ISSN: 1559-0275